Drugs / Navenibart
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07635095 | Apr → Sep 2026 overdue | — | Astria Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT05477160 | Jul 2022 → Nov 2023 | hereditary angioedema | Astria Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05695248 | Feb 2023 → Mar 2025 | hereditary angioedema | Astria Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06007677 | Sep 2023 → Mar 2031 expected | hereditary angioedema | Astria Therapeutics, Inc. | Active not recruiting | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07204938 | Oct 2025 → Jun 2031 expected | hereditary angioedema | Astria Therapeutics, Inc. | Enrolling by invitation | No outcome recorded |
| Phase 3 | NCT06842823 | Mar 2025 → Dec 2026 expected | hereditary angioedema | Astria Therapeutics, Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | navenibart | “Navenibart (STAR-0215) is a monoclonal antibody inhibitor of plasma kallikrein modified to extend circulating half-life and is under investigation for HAE prophylaxis.” PMID 40158724 ↗ Mar 20254“Navenibart administered subcutaneously via autoinjector” NCT07635095 ↗ |
| Known as | STAR-0215 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06007677 ↗ |
| Action | Inhibit | “inhibitor of plasma kallikrein” PMID 40158724 ↗ Mar 2025 |
| Modality | Monoclonal antibody | “monoclonal antibody” PMID 40158724 ↗ Mar 2025 |
| Route | Subcutaneous | “STAR-0215 will be administered as an SC bolus injection.” NCT05477160 ↗ |